15 results on '"Nocentini, Giuseppe"'
Search Results
2. Correction: Neutralization of tumor necrosis factor-related apoptosis-inducing ligand reduces spinal cord injury damage in mice
- Author
-
Cantarella, Giuseppina, Di Benedetto, Giulia, Scollo, Mimmo, Paterniti, Irene, Cuzzocrea, Salvatore, Bosco, Paolo, Nocentini, Giuseppe, Riccardi, Carlo, and Bernardini, Renato
- Published
- 2024
- Full Text
- View/download PDF
3. Impact of endocrine disruptors on peripheral blood mononuclear cells in vitro: role of gender
- Author
-
Maddalon, Ambra, Cari, Luigi, Iulini, Martina, Alhosseini, Mahdieh Naghavi, Galbiati, Valentina, Marinovich, Marina, Nocentini, Giuseppe, and Corsini, Emanuela
- Published
- 2023
- Full Text
- View/download PDF
4. Therapy with regulatory T-cell infusion in autoimmune diseases and organ transplantation: A review of the strengths and limitations
- Author
-
Alhosseini, Mahdieh Naghavi, Ebadi, Padideh, Karimi, Mohammad Hossein, Migliorati, Graziella, Cari, Luigi, Nocentini, Giuseppe, Heidari, Mozhdeh, and Soleimanian, Saeede
- Published
- 2024
- Full Text
- View/download PDF
5. AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus—A joint EAACI‐EANO position paper.
- Author
-
Turner, Michelle C., Radzikowska, Urszula, Ferastraoaru, Denisa E., Pascal, Mariona, Wesseling, Pieter, McCraw, Alexandra, Backes, Claudine, Bax, Heather J., Bergmann, Christoph, Bianchini, Rodolfo, Cari, Luigi, de las Vecillas, Leticia, Izquierdo, Elena, Lind‐Holm Mogensen, Frida, Michelucci, Alessandro, Nazarov, Petr V., Niclou, Simone P., Nocentini, Giuseppe, Ollert, Markus, and Preusser, Matthias
- Subjects
GLIOMAS ,BIOMARKERS ,SYMPTOMS ,ALLERGIES ,CLINICAL immunology ,BRAIN tumors - Abstract
Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE‐mediated diseases and glioma. Allergic disease stems from a Th2‐biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour‐immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro‐Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult‐type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune–glioma interactions to ultimately improve patient prognosis and survival. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Editorial: Targeting regulatory cells in cancer: old and new approaches in immunotherapy.
- Author
-
Cari, Luigi, Sorrentino, Rosalinda, Akkaya, Billur, and Nocentini, Giuseppe
- Subjects
REGULATORY T cells ,MYELOID-derived suppressor cells ,KILLER cells ,IMMUNE checkpoint inhibitors ,THERAPEUTICS ,OVARIAN cancer - Abstract
This document is an editorial published in Frontiers in Immunology titled "Targeting regulatory cells in cancer: old and new approaches in immunotherapy." The editorial discusses the role of regulatory cells in the tumor microenvironment (TME) and their impact on cancer progression and response to treatment. It highlights the potential of targeting regulatory cells as a therapeutic strategy to overcome immunosuppression in malignancies and improve the efficacy of existing immunotherapies. The editorial also mentions several articles included in a research topic on this subject, covering recent advances and novel approaches in targeting regulatory cells in cancer. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
7. 913 THE BILE ACIDS METABOLITES PRODUCED BY THE INTESTINAL MICROBIOTA ACT AS GPBAR1 AGONIST AND RORΓT INVERSE AGONIST DETERMINING THE COURSE OF INFLAMMATORY BOWEL DISEASE
- Author
-
Biagioli, Michele, Giorgio, Cristina Di, Massa, Carmen, Marchianò, Silvia, Bellini, Rachele, Bordoni, Martina, Urbani, Ginevra, Lachi, Ginevra, Khan, Rana Sami Ullah, Monti, Maria Chiara, Morretta, Elva, Fiorillo, Bianca, Catalanotti, Bruno, Cari, Luigi, Nocentini, Giuseppe, Ricci, Patrizia, Distrutti, Eleonora, Zampella, Angela, and Fiorucci, Stefano
- Published
- 2024
- Full Text
- View/download PDF
8. Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World.
- Author
-
Cari, Luigi, Naghavi Alhosseini, Mahdieh, Mencacci, Antonella, Migliorati, Graziella, and Nocentini, Giuseppe
- Subjects
GENE expression ,MESSENGER RNA ,COVID-19 vaccines ,VACCINES ,SARS-CoV-2 ,BACTERIAL vaccines - Abstract
Comirnaty (BNT162b2) and Spikevax (mRNA-1273) COVID-19 vaccines encode a full-length SARS-CoV-2 Spike (S) protein. To evaluate whether the S-protein expressed following treatment with the two vaccines differs in the real-world context, two cell lines were treated for 24 h with two concentrations of each vaccine, and the expression of the S-protein was evaluated using flow cytometry and ELISA. Vaccines were obtained from three vaccination centers in Perugia (Italy) that provided us with residual vaccines present in vials after administration. Interestingly, the S-protein was detected not only on the cell membrane but also in the supernatant. The expression was dose-dependent only in Spikevax-treated cells. Furthermore, the S-protein expression levels in both cells and supernatant were much higher in Spikewax-than in Comirnaty-treated cells. Differences in S-protein expression levels following vaccine treatment may be attributed to variations in the efficacy of lipid nanoparticles, differences in mRNA translation rates and/or loss of some lipid nanoparticles' properties and mRNA integrity during transport, storage, or dilution, and may contribute to explaining the slight differences in the efficacy and safety observed between the Comirnaty and Spikevax vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Overexpression of Potential Markers of Regulatory and Exhausted CD8 + T Cells in the Peripheral Blood Mononuclear Cells of Patients with B-Acute Lymphoblastic Leukemia.
- Author
-
Naghavi Alhosseini, Mahdieh, Palazzo, Marianna, Cari, Luigi, Ronchetti, Simona, Migliorati, Graziella, and Nocentini, Giuseppe
- Subjects
MONONUCLEAR leukocytes ,T cells ,SUPPRESSOR cells ,LYMPHOBLASTIC leukemia ,REGULATORY T cells ,CD8 antigen ,GENE expression - Abstract
B-acute lymphoblastic leukemia (B-ALL) is one of the most common pediatric cancers, wherein regulatory T cells (Treg) and exhausted CD8
+ T cells may be important in its development and maintenance. In this bioinformatics study, we evaluated the expression of 20 Treg/CD8 exhaustion markers and their possible roles in patients with B-ALL. The mRNA expression values of peripheral blood mononuclear cell samples from 25 patients with B-ALL and 93 healthy subjects (HSs) were downloaded from publicly available datasets. Treg/CD8 exhaustion marker expression was normalized with that of the T cell signature and correlated with the expression of Ki-67, regulatory transcription factors (FoxP3, Helios), cytokines (IL-10, TGF-β), CD8+ markers (CD8α chain, CD8β chain), and CD8+ activation markers (Granzyme B, Granulysin). The mean expression level of 19 Treg/CD8 exhaustion markers was higher in the patients than in the HSs. In patients, the expression of five markers (CD39, CTLA-4, TNFR2, TIGIT, and TIM-3) correlated positively with Ki-67, FoxP3, and IL-10 expression. Moreover, the expression of some of them correlated positively with Helios or TGF-β. Our results suggested that Treg/CD8+ T cells expressing CD39, CTLA-4, TNFR2, TIGIT, and TIM-3 favor B-ALL progression, and targeted immunotherapy against these markers could be a promising approach for treating B-ALL. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
10. Association of GILZ with MUC2, TLR2, and TLR4 in Inflammatory Bowel Disease.
- Author
-
Cari, Luigi, Rosati, Lucrezia, Leoncini, Giuseppe, Lusenti, Eleonora, Gentili, Marco, Nocentini, Giuseppe, Riccardi, Carlo, Migliorati, Graziella, and Ronchetti, Simona
- Subjects
INFLAMMATORY bowel diseases ,CROHN'S disease ,ULCERATIVE colitis ,LEUCINE zippers ,DISEASE relapse ,INVERSE relationships (Mathematics) - Abstract
Ulcerative colitis (UC) and Crohn's Disease (CD) are chronic relapsing inflammatory diseases that are caused by genetic, environmental, and immune factors. Treatment strategies are currently based on symptomatic control by immunosuppression. The glucocorticoid-induced leucine zipper (GILZ), a mediator of several effects of glucocorticoids, was recently found to be secreted by goblet cells and play a role in inflammatory bowel disease (IBD). This study investigates which genes GILZ is associated with in its role in intestinal barrier functions. We examined datasets from the Gene Expression Omnibus (GEO) and ArrayExpress profiles of the gut of healthy subjects (HSs), as well as UC and CD patients. The human colonic epithelial HT29 cell line was used for in vitro validation experiments. GILZ was significantly correlated with MUC2, TLR2, and TLR4. In particular, an inverse correlation was found between the GILZ and MUC2 in HS and patients with IBD, mostly in those with an active disease. Further, direct pairwise correlations for GILZ/TLR2 and GILZ/TLR4 were found in HSs and UC patients, but not in CD patients. Overall, our results reveal the crosstalk at the transcription level between the GILZ, MUC2, and TLRs in the mucosal barrier through common pathways, and they open up new perspectives in terms of mucosal healing in IBD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. WHEN NUTRITION BECOMES THERAPY: A PRELIMINARY STUDY OF IMMUNONUTRITION IN HOSPITALIZED OLDER AND FRAIL PATIENTS.
- Author
-
Aprea, Giulia, Cari, Luigi, Labarile, Flavia, Vizzarri, Caterina, Scamosci, Michela, Nocentini, Giuseppe, Ruggiero, Carmelinda, Mecocci, Patrizia, and Boccardi, Virginia
- Published
- 2022
12. Validation in an Independent Cohort of MiR-122, MiR-1271, and MiR-15b as Urinary Biomarkers for the Potential Early Diagnosis of Clear Cell Renal Cell Carcinoma.
- Author
-
Cochetti, Giovanni, Cari, Luigi, Maulà, Vincenza, Cagnani, Rosy, Paladini, Alessio, Del Zingaro, Michele, Nocentini, Giuseppe, and Mearini, Ettore
- Subjects
RENAL cell carcinoma ,REVERSE transcriptase polymerase chain reaction ,MICRORNA ,CANCER patients ,TUMOR markers ,SENSITIVITY & specificity (Statistics) ,POLYMERASE chain reaction ,RECEIVER operating characteristic curves ,EARLY diagnosis ,ALGORITHMS - Abstract
Simple Summary: The survival of patients with the most common type of kidney cancer (called Clear cell renal cell carcinoma—ccRCC) would dramatically improve if it was diagnosed earlier. Early diagnosis can be achieved using imaging techniques, but they are too expensive and therefore cannot be used to screen the population at risk for ccRCC. A few months ago, we published a study that evaluated the amount of certain small RNAs present in urine and showed that they are present at different levels in the urine of ccRCC patients vs. healthy subjects, and based on this discrepancy, we developed an algorithm that can anticipate the presence of kidney cancer. Such studies, however, can suffer from a technical bias called overfitting, such that the method may seem predictive even when it is not. In the present study, we sought to address this possibility and evaluate the amount of the same small RNAs in the urine of an independent cohort. As a result, we demonstrate that the previously developed algorithm has a sensitivity of 96% and specificity of 65%, thus validating this technique for potential application in the early diagnosis of ccRCC with a noninvasive assay. Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma, and the absence of symptoms in the early stages makes metastasis more likely and reduces survival. To aid in the early diagnosis of ccRCC, we recently developed a method based on urinary miR-122-5p, miR-1271-5p, and miR-15b-5p levels and three controls. The study here presented aimed to validate the previously published method through its application on an independent cohort. The expression of miRNAs in urine specimens from 28 ccRCC patients and 28 healthy subjects (HSs) of the same sex and age was evaluated by RT-qPCR. Statistical analyses were performed, including the preparation of receiver operating characteristic (ROC) curves. The mean ccRCC diameter in ccRCC patients was 4.2 ± 2.4 mm. Urinary miRNA levels were higher in patients than in HSs. The data were processed using the previously developed algorithm (7p-urinary score), and the area under the curve (AUC) of the algorithm's ROC curve was 0.81 (p-value = 0.0003), with a sensitivity of 96% and specificity of 65%. Therefore, the 7p-urinary score is a potential tool for the early diagnosis of ccRCC. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prospective, blinded clinical trial.
- Author
-
Cochetti, Giovanni, Rossi de Vermandois, Jacopo Adolfo, Maulà, Vincenza, Cari, Luigi, Cagnani, Rosy, Suvieri, Chiara, Balducci, Pierfrancesco Maria, Paladini, Alessio, Del Zingaro, Michele, Nocentini, Giuseppe, and Mearini, Ettore
- Subjects
- *
CANCER invasiveness , *BLADDER cancer , *CYSTOSCOPY , *BLIND experiment , *RECEIVER operating characteristic curves , *BLADDER , *CLINICAL trials , *CANCER relapse , *NON-muscle invasive bladder cancer , *METHYLATION , *LONGITUDINAL method - Abstract
Purpose: Currently, bladder cancer (BC) surveillance consists of periodic white light cystoscopy and urinary cytology (UC). However, both diagnostic tools have limitations. Therefore, to improve the management of recurrent BC, novel, innovative diagnostic tests are needed. The primary aim of this study was to determine the diagnostic performance of Bladder EpiCheck (BE) and photodynamic diagnosis (PDD) guided cystoscopy in the surveillance of high-risk BC. A secondary aim was to compare Bladder EpiCheck (BE) and PDD-guided cystoscopy findings with whose of UC to design a diagnostic algorithm that facilitates clinical decision making. PATIENTS AND METHODS: This was a prospective, blinded, single-arm, single-visit cohort study. All patients were under surveillance for high-risk non-muscle-invasive bladder cancer, and underwent cystoscopy with PDD and a BE test. Those who received a histological diagnosis were used as a reference population. Receiver operating characteristic curve analysis was performed to evaluate the diagnostic performance of BE, PDD-guided cystoscopy, and UC for identifying biopsy-confirmed BC lesions. The diagnostic power of the test was assessed by determining the area under the curve (AUC).Results: Forty patients were enrolled. For BE, the AUC was 0.95, and BC recurrence was detected at a sensitivity of 100% and specificity of 90.9%. For PDD, the AUC was 0.51, with a sensitivity and specificity of 61% and 41%, respectively. BE was combined with UC to create a decision-making algorithm capable of reducing the number of follow-up cystoscopies needed.Conclusion: BE is a very accurate diagnostic tool that has the potential to be useful in the surveillance of high-risk BC patients. Especially when combined with UC, it may be used to reduce the number of cystoscopies needed throughout follow-up. Conversely, the use of PDD as a diagnostic tool in such patients should be reconsidered. However, due to the small sample size of this study, a larger prospective clinical trial should be performed to confirm findings. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
14. Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data.
- Author
-
Cari, Luigi, Alhosseini, Mahdieh Naghavi, Fiore, Paolo, Pierno, Sabata, Pacor, Sabrina, Bergamo, Alberta, Sava, Gianni, and Nocentini, Giuseppe
- Subjects
- *
COVID-19 , *COVID-19 vaccines , *OLDER people , *VACCINATION , *VACCINES - Abstract
The ChAdOx1 nCoV-19 (ChA) (AstraZeneca) and Ad26.COV2.S (AD26) (Janssen) vaccines are virus-based coronavirus disease 2019 (COVID-19) vaccines used worldwide. In spring 2021, venous blood clots and thrombocytopenia were described in some vaccine recipients. We evaluated the frequency of severe adverse events (SAEs) documented in the EudraVigilance European database in young adult (18–64 years old) and older (≥65 years old) vaccine recipients up to 23 June 2021 and related them to coagulation disorders and arterial, cardiac, and nervous system events. Comparison between the frequency of SAEs and SAE-related deaths in ChA and AD26 vs. BNT162b2 COVID-19 (BNT) (Pfizer/BioNTech) vaccine recipients demonstrated: 1) ChA and AD26 recipients than BNT recipients had higher frequencies of not only SAEs caused by venous blood clots and hemorrhage, but also thromboembolic disease and arterial events, including myocardial infarction and stroke; 2) a corresponding higher frequency of SAE-related deaths. The frequency was higher in both young adults and older adults. Comparison between the frequency of SAEs and SAE-related deaths in AD26 vs. ChA recipients demonstrated in AD26 recipients: 1) lower frequency of thrombocytopenia; 2) lower frequency of SAEs in young adult recipients; 3) higher frequency of SAEs in older recipients. Interestingly, most of the venous thrombotic SAEs associated with ChA and AD26 vaccines were not associated with thrombocytopenia, suggesting that TTS (thrombosis with thrombocytopenia syndrome) is not the only type of thrombosis observed following virus-based vaccines. In conclusion, both virus-based COVID-19 vaccines show more SAEs than BNT, but the frequency of the SAE type in the different age groups differs, suggesting that the mechanisms responsible of SAEs overlap only partly. • We compared severe adverse events (SAE) frequency after vaccination with virus-based COVID-19 vaccines. • ChAdOx1 and Ad26 recipients had higher SAE frequency than BNT162b2 recipients. • Higher coagulation disorder, arterial, cardiac, and nervous system SAE frequency. • In ChAdOx1 and Ad26 recipients, thrombosis was rarely associated with thrombocytopenia. • SAE-related death frequency: higher in ChAdOx1 and Ad26 recipients vs. BNT162b2 recipients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Thrombotic events with or without thrombocytopenia in recipients of adenovirus-based COVID-19 vaccines.
- Author
-
Cari L, Naghavi Alhosseini M, Bergamo A, Pacor S, Pierno S, Sava G, and Nocentini G
- Abstract
COVID-19, the severe acute respiratory syndrome, is one of the major emergencies that have affected health care systems. Drugs and oxygen are only partially effective in saving lives in patients with severe COVID-19, and the most important protection from death is vaccination. The widespread use of COVID-19 adenovirus-based vaccines has provided evidence for the occurrence of rare venous thrombotic events including cerebral venous thrombosis and splanchnic venous thrombosis in recipients of Vaxzevria and Jcovden vaccines and the review focus on them. One year ago, thromboses in Vaxzevria recipients have been associated with thrombocytopenia in the presence of antibodies to platelet factor 4 and have been called vaccine-induced immune thrombotic thrombocytopenia (VITT). The incidence of VITT is equal to 9-31 events per one million doses of vaccines as evaluated by health agencies worldwide and is higher in female and young vaccine recipients. More recently, by using the European EudraVigilance database, it has been demonstrated that the incidence of thrombosis in recipients of adenovirus-based vaccines is 5-10 fold higher than that of VITT and 7-12 fold higher than observed in the recipients of Comirnaty, an mRNA-based vaccine, suggesting that adenovirus-based vaccines cause not only VITT but also thrombosis without thrombocytopenia (non-VITT thrombosis). The incidence of the vaccine-dependent non-VITT thrombosis is different in the adenovirus-based vaccines and the VITT/non-VITT incidence ratio depends on the severity of thrombosis and is inversely related to the age of the recipients. The possible causes and clinical implications of non-VITT thrombosis in vaccine recipients are discussed., Competing Interests: The authors have no relevant affiliation or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or material discussed in the manuscript. All this includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, and royalties., (Copyright © 2022 Cari, Naghavi Alhosseini, Bergamo, Pacor, Pierno, Sava and Nocentini.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.